Odyssey Health (OTC: ODYY) understands the severity of concussions among service members as well as the existing gaps in treatment. The Center for Disease Control (“CDC”) reports that over 430,000 military service members were diagnosed with traumatic brain injury (“TBI”) between 2000 and 2020, with 75-83% of the cases being categorized as mild (“mTBI”) or concussion. And though concussion greatly impacts military service members, there is insufficient evidence supporting, among other things, the optimal treatment strategies to mitigate these impacts. “Odyssey Health is working to develop treatments for concussion and other neurological disorders. Odyssey is developing the PRV-002, a novel, fully synthetics, non-naturally occurring neurosteroid for the treatment of concussion that is the subject of ongoing phase I clinical trials,” reads a recent article. “Data from a recently completed safety evaluation of cohort I revealed that PRV-002 is well-tolerated, meaning no severe adverse events were noted. Encouraged by the positive results from the preclinical and the ongoing phase I study, Odyssey has set sights on phase II clinical trials in the U.S., which will initially focus on the military.”
To view the full article, visit https://ibn.fm/Q2vol
About Odyssey Health Inc. (formerly Odyssey Group International Inc.)
Odyssey is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey’s corporate mission is to create, acquire and accumulate distinct assets, intellectual properties and exceptional technologies that provide meaningful medical solutions. The company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners. For more information about the company, visit https://Odysseygi.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
